2篇
您的检索式：作者名="Frank Entschladen"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 小鼠黑色素瘤某些生物学特性与其侵袭潜能的相关性研究显示文摘目的 研究具有相同起源而转移能力不同的小鼠黑色素瘤细胞系 (B16、B16F10、B16BL6 )的某些生物学特性与其侵袭潜能的相关性。方法 用重组基质膜实验考察细胞的侵袭能力 ;用分光光度法测定黑色素瘤细胞的黑色素含量 ;利用细胞运动记录分析系统研究细胞在三维胶原基质中的运动状态 ;用明胶底物酶谱法分析细胞分泌Ⅳ型胶原酶的能力 ;用端粒重复扩增 (TRAP) PCR法测定细胞的端粒酶活性。结果 B16BL6和B16F10具有较高的侵袭能力 ,其运动能力及分泌Ⅳ型胶原酶的能力亦较强 ,但B16F10的黑色素含量却较低 ,端粒酶活性在三者之间无明显差异。结论在所研究的小鼠黑色素瘤不同亚系的某些生物学特性中 ,侵袭能力与细胞运动能力、分泌Ⅳ型胶原酶的能力之间有较好的相关性 ,而与黑色素含量及端粒酶活性无直接相关性。 | 赵万洲 刘红岩 徐少锋 Frank Entschladen Bernd Niggemann KurtS.Zaenker 韩锐 | 2001 | 中华肿瘤杂志2001，23，4： | 4 |
| 2 | Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer显示文摘AIM: To investigate the expression patterns of different adrenoceptor isoforms in ovarian cancer and their association with survival and tumor recurrence. METHODS: The protein expression levels of a1 B, a2 C and b2 adrenoceptor were assessed in unselected ovarian cancer using immunohistochemistry on microarrayed archival tissue samples. A database containing clinical and pathology parameters and follow-up was usedto investigate the association between adrenoceptor isoform expression with ovarian specific survival and tumor recurrence, using univariate and multivariate statistical analysis. RESULTS: Expression of a1 B showed an association with reduced ovarian specific survival(P = 0.05; CI: 1.00-1.49) and increased tumor recurrence(P = 0.021, CI: 1.04-1.69) in the whole patient group. On subanalysis the expression of a1 B in endometrioid cancers(χ2 = 5.867, P = 0.015) was found to predict reduced ovarian specific survival and increased tumor recurrence independently of tumor grade, clinical stage and chemotherapy. An association with clinical outcome was not seen for a2 C or b2 AR.CONCLUSION: Alpha1 B adrenoceptor protein was found to predict increased risk of tumor recurrence and reduced mortality in patients with endometrioid type ovarian cancer and should be investigated as a biomarker for identifying patients at increased risk of disease progression. Furthermore, a adrenergic receptor antagonists with a1 B selectivity should be investigated as a possible adjuvant therapy for treating patients with endometrioid cancer. Proof of principle could be tested in a retrospective population study. | Dascha Deutsch Suha Deen Frank Entschladen Clare Coveney Robert Rees Kurt S Zanker Desmond George Powe | 2016 | World Journal of Obstetrics and Gynecology2016，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员